Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep330 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Study of the effects of long-term therapy DPP4i on the morphofunctional state of pancreatic endocrinocytes in the older age group in the clinic and experiment in conditions of type 2 diabetes.

Tuchina Taisiia , Babenko Alina

Introduction: DDP4i improves the function of β-cells and α-cells. However, there have been short-term follow-up and young subjects in many experimental and clinical studies. The imbalance of pancreatic endocrinocytes increases in adulthood and changes become less reversible. We decided that it would be useful to study the morphofunctional features of pancreatic endocrinocytes while taking iDPP4 in the older age group in the clinic and experimentally.<p class="abs...

ea0070aep461 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

The effect of empagliflozin treatment on biomarkers of fibrosis in patients with type 2 diabetes and a very high risk of cardiovascular events

Lebedev Denis , Babenko Alina

Objective: To evaluate the alterations of fibrosis biomarkers during empagliflozin treatment in patients with type 2 diabetes mellitus (T2DM) and a very high risk of cardiovascular events.Materials and methods: Twenty-six patients with type 2 diabetes mellitus received 10 mg of empagliflozin within 24 weeks. Inclusion criteria: women and men aged 18 to 70 years with T2DM, glycated hemoglobin (HbA1c) 7.0–11.0%, stable hypoglycemic therapy at least 1...

ea0073aep219 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Comparative evaluation of dapagliflozin and empagliflozin influence on the biomarkers of fibrosis and inflammation in patients with type 2 diabetes and very-high risk of cardiovascular events

Lebedev Denis , Babenko Alina

Recently, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardioprotective effects. However, findings for major adverse CV events (MACE) outcomes with dapagliflozin are not concordant with the empagliflozin studies and the possible mechanisms of cardioprotective effects are not fully understood. The aim of the study was to compare the two distinct SGLT2i, empagliflozin and dapagliflozin, in their influence on the biomarkers of fibrosis and inflammation.</p...

ea0063p330 | Reproductive Endocrinology 1 | ECE2019

The awareness of the side effects of the use of AAS as a factor of the conscious rejection of their use: The price of a beautiful body

Lykhonosov Mykola , Babenko Alina , Lykhonosov Pavlo

Background: The motivation for the use of AAS by men engaged in recreational activities is the improvement of body composition and strength indicators. A deterrent to the use of AAS can be awareness of the side effects of their use, in particular the development of secondary hypogonadism.Aim: To study the awareness of AAS users about the negative impact of this class of drugs on the body.Methods: An individual anonymous corresponde...

ea0016p720 | Thyroid | ECE2008

Level of von Willebrand factor in thyrotoxicosis of a various genesis

Babenko Alina , Cadinskaya Margarita , Grineva Elena

In several studies, the state of the endothelial function is analyzed in clinical thyrotoxicosis. Increased level of von Willebrand factor is detected. Many events of association of trombosis at these patients with high level of VWF are described. An association between autoimmune thyroid disease and pulmonary arterial hypertension (PAH) has been reported too. We have studied factors which influence on level of VWF at patients with a clinical thyrotoxicosis of a various genesi...

ea0014p322 | (1) | ECE2007

Influence of a subclinical thyrotoxicosis on heart in various age-grades

Babenko Alina , Grineva Elena , Vashrameeva Natalia

Subclinical thyrotoxicosis (ST) characterized by low serum TSH and normal FT4 and FT3 concentrations. ST may cause changes of geometry of heart and developments of diastolic dysfunction. Influence of ST on this evolutions depending on age of patients, duration of S?, effect of TSH level is not clear. In present research the effects of ST on changes of EchoCG at a different age were studied. The present study includes 66 normotensive patients with ST witho...

ea0070aep826 | Reproductive and Developmental Endocrinology | ECE2020

Assessment of the status of the pituitary-gonadal axis in men who have been using androgenic anabolic steroids for a long time

Lykhonosov Mykola , Babenko Alina Y. , Makarin Viktor A. , Fedotov Yuri N

Background: The study of the state of the pituitary-gonadal axis (PGA) in users of anabolic androgenic steroids (AAS) is important. The severity of inhibition of luteinizing (LH), follicle-stimulating (FSH) hormones, total testosterone (Tt), inhibin B may depend on the type of AAS used, its doses, the simultaneous use of several types of AAS and the duration of their administration.Aim: To evaluate the levels of LH, FSH, Tt and Inhibin B depending on the...

ea0070aep1047 | Hot topics (including COVID-19) | ECE2020

Prediction of weight loss response to liraglutide

Mosikian Anna , Alekseenko Tatiana , Martjanova Maria , Babenko Alina

Background: Obesity is a significant risk factor for type 2 diabetes mellitus (T2D), hypertension and ischemic heart disease development. Moreover, in patients with already diagnosed T2D, obesity puts a crimp in achievement of glycemic target. Thus, body weight reduction is important both to prevent T2D and to treat it successfully. However lifestyle habits, diet and physical activity are the key factors of T2D prevention and treatment, eating disorders and disturbed appetite ...

ea0056p471 | Diabetes complications | ECE2018

Clinical and laboratory predictors of positive renal effects of vildagliptin

Bayrasheva Valentina , Pchelin Ivan , Babenko Alina , Chefu Svetlana , Grineva Elena

Accumulating facts show that incretin-modulating therapy could be beneficial in both glycemic control and nephroprotection in type 2 diabetes (DM2). Clinical evidence for nephroprotective potential of DPP-4 inhibitors is limited and predictive determinants are unknown. The study conducted with DM2 patients aimed to assess renal effects of vildagliptin addition and identify their clinical and laboratory predictors. The study enrolled 44 insulin-treated male and female type 2 di...

ea0037gp.15.07 | Diabetes and obesity – basic | ECE2015

Nephroprotective properties of metformin and vildagliptin: experimental facts in type 2 diabetes

Bayrasheva Valentina , Grineva Elena , Babenko Alina , Dmitriev Yurii , Shatalov Ivan , Chefu Svetlana , Ivanova Alexandra

Background: Recent studies have demonstrated antioxidant and anti-inflammatory properties of metformin and vildagliptin, that could result in some positive effects on kidney function in diabetes. Indeed, in our previous study vildagliptin attenuated routine renal dysfunction markers in insulinopenic diabetic rats, however metformin didn’t improve it. In our current study we evaluated not only glomerular dysfunction marker (albuminuria), but also novel markers of proximal ...